CORCEPT THERAPEUTICS INC
No enriched coverage for $CORT in the last 7 days.
Guyer William (Chief Development Officer) sold 16,300 shares of CORCEPT THERAPEUTICS INC (CORT) at an average of $113.43 ($113.18–$114.04, $1.85M total) across 2 trades on 2026-08-10 under a Rule 10b5-1 trading plan.
Corcept Therapeutics (CORT) reported fiscal 2026 Q2 results with record revenue of $256.1 million, up 32% year over year, and net income of $43 million, up 22.9%. The company had $545 million in cash and investments and raised 2026 revenue guidance to as much as $1.2 billion, sending shares to a 52-week high.
Maduck Sean (See Remarks) sold 20,305 shares of CORCEPT THERAPEUTICS INC (CORT) at $114.70 ($2.33M total) on 2026-08-03 under a Rule 10b5-1 trading plan.
Recent CORT coverage spans insider activity, market movers and earnings.
In the last 30 days, CORT insiders filed 19 SEC Form 4 transactions — no purchases and 19 sales ($14.1M). The most active reporter was Mokari Atabak, Chief Financial Officer, with 13 filings. 95% of those filings were made under pre-arranged Rule 10b5-1 plans.
A routine 10b5-1 open-market sale by a senior officer, with no stated operational or financial catalyst in the filing.
Guidance lift plus strong reported results likely supports momentum and re-rates near-term expectations.
This is a routine 10b5-1 insider sale disclosure, not a new operating or financial catalyst.
This is a disclosed insider open-market sale under a Form 4, with no 10b5-1 plan stated.
This is a routine insider-sale disclosure with no new operational or financial guidance, but it can modestly affect near-term sentiment.
alphai scores every news story that mentions CORT with an AI model for sentiment and relevance, and aggregates insider trades from CORCEPT THERAPEUTICS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Guyer William (Chief Development Officer) sold 16,300 shares of CORCEPT THERAPEUTICS INC (CORT) at an average of $113.43 ($113.18–$114.04, $1.85M total) across 2 trades on 2026-08-10 under a Rule 10b5-1 trading plan.
1 min readCorcept Therapeutics (CORT) reported fiscal 2026 Q2 results with record revenue of $256.1 million, up 32% year over year, and net income of $43 million, up 22.9%. The company had $545 million in cash and investments and raised 2026 revenue guidance to as much as $1.2 billion, sending shares to a 52-week high.
3 min readMaduck Sean (See Remarks) sold 20,305 shares of CORCEPT THERAPEUTICS INC (CORT) at $114.70 ($2.33M total) on 2026-08-03 under a Rule 10b5-1 trading plan.
1 min readLyon Joseph Douglas (See Remarks) sold 1,540 shares of CORCEPT THERAPEUTICS INC (CORT) at $114.16 ($0.18M total) on 2026-08-03.
1 min readMokari Atabak (Chief Financial Officer) sold 80,000 shares of CORCEPT THERAPEUTICS INC (CORT) at an average of $114.71 ($105.54–$120.67, $9.18M total) across 13 trades on 2026-07-30 under a Rule 10b5-1 trading plan.
2 min readUS Q2 GDP rose 1.5% (q/q annualized) vs 2.0% expected, while core PCE eased to 3.4% from 4.4%. Stocks settled sharply higher as megacap tech earnings expectations rose, with Bloomberg BI projecting Q2 earnings up 23%. Microsoft led after reporting Q4 Azure and cloud revenue ex-forex +43%. Bitcoin rose over 2%, lifting crypto stocks.
7 min readUS stocks rose as investors digested strong Q2 earnings expectations and results, led by Microsoft. The article cites Bloomberg Intelligence forecasts for Q2 earnings up about 23% and notes 86% of 243 S&P 500 firms beat estimates. It also reports chip and AI-infrastructure gains tied to Lam Research and other semis, while some software names fell.
7 min readThe following biotech stocks reached 52-week highs on July 30, 2026, driven by key catalysts such as positive quarterly reports or announced settlement agreements. Corcept Therapeutics Incorporated (CORT) Corcept is a biopharmaceutical company engaged in developing medications for metabolic, oncologic, and neurologic diseases. Shares surged over 30% on Thursday to a 52-week high of $122.21.
6 min readVieira said the company continues to add patients weekly and is seeking to expand use among additional physicians and practices. He said Corcept expects LIFYORLI's U.S. annual revenue in platinum-resistant ovarian cancer alone to exceed $1 billion as adoption grows. In its pivotal ROSELLA study, LIFYORLI combined with nab-paclitaxel chemotherapy met both primary endpoints, according to Chief Executive Officer Joe Belanoff.
6 min readToday's top gainers included Glucotrack, whose subsidiary announced progress in the development strategy for LT-100, a novel non-narcotic therapy; Nuwellis, following expanded clinical recognition for its Aquadex therapy; Bausch Health, after reporting strong second-quarter 2026 results and raising its outlook; and Corcept Therapeutics, after posting robust second-quarter 2026 results, among others. Read on… GCTK's LT-100 Program Moves Forward Glucotrack Inc.
6 min read